December 19, 2025 · Form 4 insider transaction
Bodenstedt Matthias bought 294,473 shares of MOONLAKE THERAPEUTICS, a transaction worth N/A. The trade was recorded as conversion of a derivative and disclosed on an SEC Form 4, filed 3 days after the transaction.
On December 19, 2025, the Reporting Person exchanged 8,754 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 294,473 Class A ordinary shares of the Issuer. In connection with the exchange, 294,473 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.; The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.